Brainsway vs DarioHealth
BWAY and DRIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BWAY and DRIO compare
Brainsway grew revenue faster over the last twelve months (27.3% versus −22.6% for DarioHealth).
DarioHealth scores higher on the StockData Score (8 against 5 for Brainsway), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BWAY | DRIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $11.3M |
| Share price | $9.39 | $1.15 |
| Change, 1 year | 17.3% | −88.4% |
| Change, 5 years | 156% | −99.6% |
| Beta (5Y) | 1.65 | −0.03 |
| Employees | 129 | 160 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.3× |
| P/S | – | 0.5× |
| P/B | – | 0.2× |
| PEG | – | 0.01 |
| FCF yield | – | −226% |
| Fair value | – | $92.75 |
| Margin of safety | – | 98.8% |
| Growth | ||
| Revenue growth (TTM) | 27.3% (better) | −22.6% |
| Revenue growth, 5Y average | 18.8% | 24.2% (better) |
| EPS growth (TTM) | 260% | – |
| EPS growth, 5Y average | – | 20.3% |
| Profitability | ||
| Gross margin | 75.4% (better) | 58.2% |
| Operating margin | 8.3% (better) | −152% |
| Net margin | – | −170% |
| FCF margin | – | −121% |
| Return on equity | – | −59.9% |
| Return on invested capital | – | −34.8% |
| Financial health | ||
| Debt / equity | – | 0.56 |
| Interest coverage | 2.0× (better) | −7.0× |
| Current ratio | 3.59 (better) | 2.31 |
| Altman Z-score | – | −7.34 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 29.2% | 15.0% |
| Held by insiders | 25.5% | 13.7% |
| Insider net buying, 12 months | – | $100K |
| Short interest, % of float | – | 1.4% |
Go deeper
- BWAY stock overview
- BWAY income statement
- BWAY valuation and score
- DRIO stock overview
- DRIO income statement
- DRIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.